XML 48 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1

Revenues - Disaggregation of Revenues (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Disaggregation of Revenue [Line Items]
Revenues	$ 5,648	$ 7,141	$ 10,736	$ 13,646
U.S.
Disaggregation of Revenue [Line Items]
Revenues	4,083	5,004	7,630	9,473
Europe
Disaggregation of Revenue [Line Items]
Revenues	1,084	1,458	2,141	2,817
Other International
Disaggregation of Revenue [Line Items]
Revenues	481	679	965	1,356
Atripla
Disaggregation of Revenue [Line Items]
Product revenue	349	475	663	927
Atripla | U.S.
Disaggregation of Revenue [Line Items]
Product revenue	274	334	502	650
Atripla | Europe
Disaggregation of Revenue [Line Items]
Product revenue	39	86	90	180
Atripla | Other International
Disaggregation of Revenue [Line Items]
Product revenue	36	55	71	97
Biktarvy
Disaggregation of Revenue [Line Items]
Product revenue	185	0	220	0
Biktarvy | U.S.
Disaggregation of Revenue [Line Items]
Product revenue	183	0	218	0
Biktarvy | Europe
Disaggregation of Revenue [Line Items]
Product revenue	2	0	2	0
Biktarvy | Other International
Disaggregation of Revenue [Line Items]
Product revenue	0	0	0	0
Complera/Eviplera
Disaggregation of Revenue [Line Items]
Product revenue	199	254	389	507
Complera/Eviplera | U.S.
Disaggregation of Revenue [Line Items]
Product revenue	82	112	149	224
Complera/Eviplera | Europe
Disaggregation of Revenue [Line Items]
Product revenue	103	127	212	252
Complera/Eviplera | Other International
Disaggregation of Revenue [Line Items]
Product revenue	14	15	28	31
Descovy
Disaggregation of Revenue [Line Items]
Product revenue	403	286	764	537
Descovy | U.S.
Disaggregation of Revenue [Line Items]
Product revenue	311	232	585	441
Descovy | Europe
Disaggregation of Revenue [Line Items]
Product revenue	78	47	153	84
Descovy | Other International
Disaggregation of Revenue [Line Items]
Product revenue	14	7	26	12
Genvoya
Disaggregation of Revenue [Line Items]
Product revenue	1,160	857	2,242	1,626
Genvoya | U.S.
Disaggregation of Revenue [Line Items]
Product revenue	904	710	1,757	1,379
Genvoya | Europe
Disaggregation of Revenue [Line Items]
Product revenue	207	125	393	212
Genvoya | Other International
Disaggregation of Revenue [Line Items]
Product revenue	49	22	92	35
Odefsey
Disaggregation of Revenue [Line Items]
Product revenue	385	258	727	485
Odefsey | U.S.
Disaggregation of Revenue [Line Items]
Product revenue	303	230	582	433
Odefsey | Europe
Disaggregation of Revenue [Line Items]
Product revenue	77	27	135	50
Odefsey | Other International
Disaggregation of Revenue [Line Items]
Product revenue	5	1	10	2
Stribild
Disaggregation of Revenue [Line Items]
Product revenue	187	293	361	602
Stribild | U.S.
Disaggregation of Revenue [Line Items]
Product revenue	144	225	277	451
Stribild | Europe
Disaggregation of Revenue [Line Items]
Product revenue	34	54	63	121
Stribild | Other International
Disaggregation of Revenue [Line Items]
Product revenue	9	14	21	30
Truvada
Disaggregation of Revenue [Line Items]
Product revenue	765	812	1,417	1,526
Truvada | U.S.
Disaggregation of Revenue [Line Items]
Product revenue	649	567	1,156	1,031
Truvada | Europe
Disaggregation of Revenue [Line Items]
Product revenue	86	184	183	373
Truvada | Other International
Disaggregation of Revenue [Line Items]
Product revenue	30	61	78	122
Other HIV
Disaggregation of Revenue [Line Items]
Product revenue	19	11	32	26
Other HIV | U.S.
Disaggregation of Revenue [Line Items]
Product revenue	11	7	20	21
Other HIV | Europe
Disaggregation of Revenue [Line Items]
Product revenue	3	2	4	3
Other HIV | Other International
Disaggregation of Revenue [Line Items]
Product revenue	5	2	8	2
Revenue share - Symtuza
Disaggregation of Revenue [Line Items]
Product revenue	13	0	20	0
Revenue share - Symtuza | U.S.
Disaggregation of Revenue [Line Items]
Product revenue	0	0	0	0
Revenue share - Symtuza | Europe
Disaggregation of Revenue [Line Items]
Product revenue	13	0	20	0
Revenue share - Symtuza | Other International
Disaggregation of Revenue [Line Items]
Product revenue	0	0	0	0
AmBisome
Disaggregation of Revenue [Line Items]
Product revenue	103	92	210	184
AmBisome | U.S.
Disaggregation of Revenue [Line Items]
Product revenue	14	8	31	17
AmBisome | Europe
Disaggregation of Revenue [Line Items]
Product revenue	55	50	111	102
AmBisome | Other International
Disaggregation of Revenue [Line Items]
Product revenue	34	34	68	65
Epclusa
Disaggregation of Revenue [Line Items]
Product revenue	500	1,171	1,036	2,063
Epclusa | U.S.
Disaggregation of Revenue [Line Items]
Product revenue	239	864	508	1,599
Epclusa | Europe
Disaggregation of Revenue [Line Items]
Product revenue	168	248	366	386
Epclusa | Other International
Disaggregation of Revenue [Line Items]
Product revenue	93	59	162	78
Harvoni
Disaggregation of Revenue [Line Items]
Product revenue	331	1,382	679	2,753
Harvoni | U.S.
Disaggregation of Revenue [Line Items]
Product revenue	230	984	464	1,910
Harvoni | Europe
Disaggregation of Revenue [Line Items]
Product revenue	22	230	78	473
Harvoni | Other International
Disaggregation of Revenue [Line Items]
Product revenue	79	168	137	370
Letairis
Disaggregation of Revenue [Line Items]
Product revenue	244	230	448	441
Letairis | U.S.
Disaggregation of Revenue [Line Items]
Product revenue	244	230	448	441
Letairis | Europe
Disaggregation of Revenue [Line Items]
Product revenue	0	0	0	0
Letairis | Other International
Disaggregation of Revenue [Line Items]
Product revenue	0	0	0	0
Ranexa
Disaggregation of Revenue [Line Items]
Product revenue	208	200	403	353
Ranexa | U.S.
Disaggregation of Revenue [Line Items]
Product revenue	208	200	403	353
Ranexa | Europe
Disaggregation of Revenue [Line Items]
Product revenue	0	0	0	0
Ranexa | Other International
Disaggregation of Revenue [Line Items]
Product revenue	0	0	0	0
Vemlidy
Disaggregation of Revenue [Line Items]
Product revenue	76	22	134	33
Vemlidy | U.S.
Disaggregation of Revenue [Line Items]
Product revenue	59	21	106	32
Vemlidy | Europe
Disaggregation of Revenue [Line Items]
Product revenue	3	1	6	1
Vemlidy | Other International
Disaggregation of Revenue [Line Items]
Product revenue	14	0	22	0
Viread
Disaggregation of Revenue [Line Items]
Product revenue	82	300	179	560
Viread | U.S.
Disaggregation of Revenue [Line Items]
Product revenue	16	141	23	258
Viread | Europe
Disaggregation of Revenue [Line Items]
Product revenue	32	76	62	147
Viread | Other International
Disaggregation of Revenue [Line Items]
Product revenue	34	83	94	155
Vosevi
Disaggregation of Revenue [Line Items]
Product revenue	109	0	216	0
Vosevi | U.S.
Disaggregation of Revenue [Line Items]
Product revenue	86	0	172	0
Vosevi | Europe
Disaggregation of Revenue [Line Items]
Product revenue	20	0	36	0
Vosevi | Other International
Disaggregation of Revenue [Line Items]
Product revenue	3	0	8	0
Yescarta
Disaggregation of Revenue [Line Items]
Product revenue	68	0	108	0
Yescarta | U.S.
Disaggregation of Revenue [Line Items]
Product revenue	68	0	108	0
Yescarta | Europe
Disaggregation of Revenue [Line Items]
Product revenue	0	0	0	0
Yescarta | Other International
Disaggregation of Revenue [Line Items]
Product revenue	0	0	0	0
Zydelig
Disaggregation of Revenue [Line Items]
Product revenue	39	35	72	70
Zydelig | U.S.
Disaggregation of Revenue [Line Items]
Product revenue	17	19	31	34
Zydelig | Europe
Disaggregation of Revenue [Line Items]
Product revenue	22	16	40	35
Zydelig | Other International
Disaggregation of Revenue [Line Items]
Product revenue	0	0	1	1
Other
Disaggregation of Revenue [Line Items]
Product revenue	115	368	221	730
Other | U.S.
Disaggregation of Revenue [Line Items]
Product revenue	27	98	56	158
Other | Europe
Disaggregation of Revenue [Line Items]
Product revenue	41	126	56	246
Other | Other International
Disaggregation of Revenue [Line Items]
Product revenue	47	144	109	326
Product sales
Disaggregation of Revenue [Line Items]
Product revenue	5,540	7,046	10,541	13,423
Product sales | U.S.
Disaggregation of Revenue [Line Items]
Product revenue	4,069	4,982	7,596	9,432
Product sales | Europe
Disaggregation of Revenue [Line Items]
Product revenue	1,005	1,399	2,010	2,665
Product sales | Other International
Disaggregation of Revenue [Line Items]
Product revenue	466	665	935	1,326
Royalty, contract and other revenues
Disaggregation of Revenue [Line Items]
Revenues	108	95	195	223
Royalty, contract and other revenues | U.S.
Disaggregation of Revenue [Line Items]
Revenues	14	22	34	41
Royalty, contract and other revenues | Europe
Disaggregation of Revenue [Line Items]
Revenues	79	59	131	152
Royalty, contract and other revenues | Other International
Disaggregation of Revenue [Line Items]
Revenues	$ 15	$ 14	$ 30	$ 30

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=gild_OtherInternationalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_AntiviralProductsAtriplaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_AntiviralProductsBiktarvyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_AntiviralProductsCompleraEvipleraMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_AntiviralProductsDescovyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_AntiviralProductsGenvoyaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_AntiviralProductsOdefseyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_AntiviralProductsStribildMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_AntiviralProductsTruvadaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_AntiviralProductsEpclusaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_AntiviralProductsHarvoniMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_AntiviralProductsVemlidyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_AntiviralProductsVireadMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_AntiviralProductsVoseviMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_OtherProductsOtherMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: